Stem Cell Transplantation for Follicular Lymphoma Relapsed/Refractory After Prior Rituximab
Stem Cell Transplantation for Follicular Lymphoma Relapsed/Refractory After Prior Rituximab
复制标题
DOI：
10.1002/cncr.28243
复制
发表时间：
2013-10-15
期刊：
影响因子：
6.2
通讯作者：
Friedberg, Jonathan W.
中科院分区：
文献类型：
--
作者：
Evens, Andrew M.;Vanderplas, Ann;Friedberg, Jonathan W.
背景在利妥昔单抗治疗后，复发/难治性滤泡性淋巴瘤(FL)与干细胞移植(SCT)相关的结果和预后没有明确的定义。方法通过国家综合癌症网络(NCCN)淋巴瘤预后研究，184名复发/难治性FL患者接受自体SCT(自体SCT)或异体SCT(异体SCT)治疗后复发(分别为35%和8%，P=0.006)。结果接受自体SCT(N=136)的患者比接受同种SCT(N=48)的患者年龄更大(分别为54岁和51岁，P=.01)，并且更频繁地发生3级FL(分别为35%和8%，P=.006)。接受异基因干细胞移植的患者接受了更多的先前治疗(分别为4例和3例，P
BACKGROUNDStem cell transplant (SCT)-related outcomes and prognostication for relapsed/refractory follicular lymphoma (FL) are not well-defined in the post-rituximab era.METHODSThrough the National Comprehensive Cancer Network (NCCN) lymphoma outcomes study, 184 patients with relapsed/refractory FL who underwent autologous SCT (autoSCT) or allogenic SCT (alloSCT) following disease relapse after prior rituximab-based therapy were examined.RESULTSPatients who underwent autoSCT (N=136) were older compared with patients who underwent alloSCT (N=48) (54 versus 51 years, respectively, P=.01) and more frequently had grade 3 FL (35% versus 8%, respectively, P=.006). Patients who underwent alloSCT received more prior therapies (4 versus 3, respectively, P